Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia

Journal of Clinical Oncology

Volumn 21, Issue 16, 2003, Pages 3158-3167

  Vadhan Raj, Saroj ^a   Patel, Shreyaskumar ^a   Bueso Ramos, Carlos ^a   Folloder, Jody ^a   Papadopolous, Nicholas ^a   Burgess, Andrew ^a   Broemeling, Lyle D ^a   Broxmeyer, Hal E ^a   Benjamin, Robert S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; IFOSFAMIDE; RECOMBINANT THROMBOPOIETIN; ANTINEOPLASTIC AGENT; RECOMBINANT PROTEIN; THROMBOPOIETIN;

ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG DOSE REGIMEN; HUMAN; MAJOR CLINICAL STUDY; MEGAKARYOCYTE; PRIORITY JOURNAL; SARCOMA; SUBCLAVIAN VEIN THROMBOSIS; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; VEIN THROMBOSIS; ADOLESCENT; ADULT; AGED; BONE MARROW; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COHORT ANALYSIS; DIET THERAPY; DRUG ADMINISTRATION; DRUG EFFECT; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; COHORT STUDIES; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; HUMANS; IFOSFAMIDE; MIDDLE AGED; RECOMBINANT PROTEINS; SARCOMA; THROMBOCYTOPENIA; THROMBOPOIETIN;

EID: 0041411416     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.08.003     Document Type: Article

References (30)

1. McCullough J: Current issues with platelet transfusion in patients with cancer. Semin Hematol 37:3-10, 2000 (suppl 4)
2. Slichter SJ: Optimizing platelet transfusions in chronically thrombocytopenic patients. Semin Hematol 35:269-278, 1998
3. Pisciotto PT, Benson K, Hume H, et al: Prophylactic versus therapeutic platelet transfusion practices in hematology and/or oncology patients. Transfusion 35:498-502, 1995
4. Schiffer CA, Anderson KC, Bennett CL, et al: Platelet transfusion for patients with cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1519-1538, 2001
5. Vadhan-Raj S, Kudelka AP, Garrison L, et al: Effects of interleukin-1 alpha on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer. J Clin Oncol 12:707-714, 1994
6. Biesma B, Willemse PH, Mulder NH, et al: Effects of interleukin-3 after chemotherapy for advanced ovarian cancer. Blood 80:1141-1148, 1992
7. Veldhuis GJ, Willemse PH, Sleijfer DT, et al: Toxicity and efficacy of escalating dosages of recombinant human interleukin-6 after chemotherapy in patients with breast cancer or non-small-cell lung cancer. J Clin Oncol 13:2585-2593, 1995
8. Vadhan-Raj S, Papadopoulos NE, Burgess MA, et al: Effects of P1XY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma. J Clin Oncol 12:715-724, 1994
9. D'Hondt V, Weynants P, Humbler Y, et al: Dose-dependent interleukin-3 stimulation of thrombopoiesis in patients with small-cell lung carcinoma before and following chemotherapy: A placebo-controlled randomized phase Ib study. J Clin Oncol 11:2063-2071, 1993
10. Tepler I, Elias L, Smith JW, et al: A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 87:3607-3614, 1996
11. Isaacs C, Robert NJ, Bailey FA, et al.: Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol 15:3368-3377, 1997
12. de Sauvage FJ, Hass PE, Spencer SD, et al: Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 369:533-538, 1994
13. Kuter DJ, Beeler DL, Rosenberg RD: The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A 91:11104-11108, 1994
14. Kaushansky K, Lok S, Holly RD, et al: Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 369:568-571, 1994
15. Fanucchi M, Glaspy J, Crawford J, et al: Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 336:404-409, 1997
16. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al: Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 126:673-681, 1997
17. Basser RL, Rasko JEJ, Clarke K, et al: Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 89:3118-3128, 1997
18. Vadhan-Raj S, Patel S, Broxmeyer HE, et al: Phase I-II investigation of recombinant human thrombopoietin (rhTPO) in patients with sarcoma receiving high dose chemotherapy (CT) with adriamycin (A) and ifosfamide (I). Blood 88:448a, 1996 (suppl 1, abstr 1779)
19. Schiffer CA, Miller K, Larson RA, et al: A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood 95:2530-2535, 2000
20. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al: Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 132:364-368, 2000
21. Chu E, DeVita VT: Chemotherapeutic and biologic drugs, in Physicians' Cancer Chemotherapy Drug Manual. Sudbury, MA, Jones and Bartlett Publishers, 2001, pp 37-476
22. Chu E, Mota A, Nabbout N, et al: Common chemotherapy regimens in clinical practice, in Physicians' Cancer Chemotherapy Drug Manual. Sudbury, MA, Jones and Bartlett Publishers, 2001, pp 501-580
23. Patel S, Vadhan-Raj S, Burgess M, et al: Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol 21:317-321, 1998
24. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164-170, 1991
25. Neumunaitis J, Robinowe S, Singer J, et al: Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 324:1773-1778, 1991
26. Borge OJ, Ramsfjell V, Veiby OP, et al: Thrombopoietin, but not erythropoietin promotes viability and inhibits apoptosis of multipotent murine hematopoietic progenitor cells in vitro. Blood 88:2859-2870, 1996
27. Ritchie A, Vadhan-Raj S, Broxmeyer HE: Thrombopoietin suppresses apoptosis and behaves as a survival factor for the human growth factor-dependent cell line, M07e. Stem Cells 14:330-336, 1996
28. Wlodarski P, Wasik M, Ratajczak MZ, et al: Role of p53 in hematopoietic recovery after cytotoxic treatment. Blood 91:2998-3006, 1998
29. Nagasawa T, Osada M, Komero T, et al: In vitro and in vivo deprivation of thrombopoietin induces megakaryocytic apoptosis and regulates platelet production. Exp Hematol 25:897, 1997 (abstr 591)
30. Zauli G, Vitale M, Falcieri E, et al: In vitro senescence and apoptotic cell death of human megakaryocytes. Blood 90:2234-2243, 1997